Metastatic Breast Cancer — Optimizing the Use of Oral Selective Estrogen Receptor Degraders: Part 2
Oncology Today with Dr Neil Love
00:00
AKT and PI3K Combinations in ESR1 Mutants
Discussion of capivasertib and PI3K inhibitor data, subgroup effects post-CDK4/6, and how PI3K pathway alters sequencing decisions.
Play episode from 23:03
Transcript
